NOP receptor mediates anti-analgesia induced by agonist-antagonist opioids

Neuroscience. 2014 Jan 17:257:139-48. doi: 10.1016/j.neuroscience.2013.10.061. Epub 2013 Nov 1.

Abstract

Clinical studies have shown that agonist-antagonist opioid analgesics that produce their analgesic effect via action on the kappa-opioid receptor, produce a delayed-onset anti-analgesia in men but not women, an effect blocked by co-administration of a low dose of naloxone. We now report the same time-dependent anti-analgesia and its underlying mechanism in an animal model. Using the Randall-Selitto paw-withdrawal assay in male rats, we found that nalbuphine, pentazocine, and butorphanol each produced analgesia during the first hour followed by anti-analgesia starting at ∼90min after administration in males but not females, closely mimicking its clinical effects. As observed in humans, co-administration of nalbuphine with naloxone in a dose ratio of 12.5:1 blocked anti-analgesia but not analgesia. Administration of the highly selective kappa-opioid receptor agonist U69593 produced analgesia without subsequent anti-analgesia, and confirmed by the failure of the selective kappa antagonist nor-binaltorphimine to block nalbuphine-induced anti-analgesia, indicating that anti-analgesia is not mediated by kappa-opioid receptors. We therefore tested the role of other receptors in nalbuphine anti-analgesia. Nociceptin/orphanin FQ (NOP) and sigma-1 and sigma-2 receptors were chosen on the basis of their known anti-analgesic effects and receptor binding studies. The selective NOP receptor antagonists, JTC801, and J-113397, but not the sigma receptor antagonist, BD 1047, antagonized nalbuphine anti-analgesia. Furthermore, the NOP receptor agonist NNC 63-0532 produced anti-analgesia with the same delay in onset observed with the three agonist-antagonists, but without producing preceding analgesia and this anti-analgesia was also blocked by naloxone. These results strongly support the suggestion that clinically used agonist-antagonists act at the NOP receptor to produce anti-analgesia.

Keywords: ANOVA; EDTA; FQ; HEPES; N-(2-hydroxyethyl)piperazine-N′-2-ethanesulfonic acid; NOP; analysis of variance; anti-analgesia; ethylenediaminetetraacetic acid; nalbuphine; nociceptin/orphanin; nociceptin/orphanin FQ receptor; nor-binaltorphimine; norBNI; receptor; κ-opioids.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Analgesics / pharmacology*
  • Analysis of Variance
  • Animals
  • Benzeneacetamides
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Female
  • Male
  • Nalbuphine / pharmacology
  • Naloxone / pharmacology
  • Narcotic Antagonists / pharmacology*
  • Nociceptin
  • Opioid Peptides / metabolism*
  • Pain Measurement / drug effects*
  • Pain Threshold / drug effects*
  • Protein Binding / drug effects
  • Pyrrolidines
  • Rats
  • Rats, Sprague-Dawley
  • Sex Differentiation

Substances

  • Analgesics
  • Benzeneacetamides
  • Narcotic Antagonists
  • Opioid Peptides
  • Pyrrolidines
  • Naloxone
  • U 69593
  • Nalbuphine